There is one clinical trial.
This randomized, controlled trial will assess the efficacy and safety of pulsed iNO in subjects with COVID-19 who are hospitalized and require supplemental oxygen.
Description: As assessed per treating physician's discretion.
Measure: Incidence of treatment emergent adverse events Time: Up to 14 daysDescription: Incidence of hypoxemia and hypotension as assessed per treating physician's discretion.
Measure: Incidence of adverse events Time: Up to 6 hoursDescription: Incidence of increase to > 5% total methemoglobin as assessed by pulse oximetry.
Measure: Incidence of methemoglobinemia Time: Up to 14 daysDescription: Worsening respiratory status as defined by any one of the following: Implementation of High Flow Nasal Cannula (HFNC), non-rebreather mask, non-invasive ventilation, intubation and mechanical ventilation or need for intubation (in the event the patient is not intubated due to do not intubate (DNI) or do not resuscitate (DNR) status).
Measure: Number of participants with progression of respiratory failure Time: Up to 14 daysDescription: The number of days until hypoxemia is resolved as per treating physician assessment
Measure: Time until resolution of hypoxemia Time: Up to 14 daysDescription: Incidence of death during hospitalization and after discharge up to 28 days
Measure: Incidence of mortality Time: Up to 28 daysDescription: Number of days of hospitalization
Measure: Duration of hospitalization Time: Up to 28 days